Apart from blood-based analysis, miRNA from cerebrospinal fluid (CSF) has gained increasing attention in studies exploring for potential AD biomarkers, as Aβ, total tau, and phosphorylated tau levels in CSF can support the clinical diagnosis of AD with acceptable sensitivity and specificity (Ghidoni et al., 2011; Blennow and Zetterberg, 2013; Lleo et al., 2015). This evidence concerns the gene MAPT and Alzheimer disease.